Ulcerative Colitis Market Forecast - Epidemiology & Pipeline Analysis 2022-2027

List of Tables

The ulcerative colitis market is expected to grow at a CAGR of 8.77% during 2022-2027.

Ulcerative colitis is a chronic inflammatory bowel disease (IBD) in which abnormal immune system reactions cause inflammation and ulcers on the inner lining of the large intestine. The ulcerative colitis epidemiology provides insights into the historical and current patient pools and forecasted trends for eight (8MM) major countries. The ulcerative colitis segment covers the historical and forecasted epidemiology data in the US, EU5 (including France, Germany, Italy, Spain, and the UK), China, and Japan from 2021-2027. The Ulcerative colitis epidemiology data are studied through all possible divisions to give a better understanding of the disease scenario in 8MM.

This report provides a detailed analysis of the drugs available for the treatment of ulcerative colitis. The report covers a detailed drug description including drug name, sponsor name, route of administration, molecule type, mechanism of action of the drug, clinical studies, NDA approvals, and Ulcerative colitis (Ulcerative colitis) collaborations, licensing, mergers and acquisition, designations, and other product-related details.

According to Arizton's estimate, the diagnosed incident cases ofinflammatory bowel disease were high in the United States, followed by China and the UK in 2020. The increasing prevalence of ulcerative colitis is driving the growth of the ulcerative colitis drug market. According to the estimates, one million people were affected by inflammatory bowel disease in the US in 2019.

MARKET DRIVERS

Launch of New Therapies: The USFDA approved small molecules such as Jyseleca (Filgotinib) and Rinvoq (Upadacitinib) in 2022 to treat moderate-to-severe ulcerative colitis. The launch of approved small molecules and further uptake in biological therapies will lead to significant growth in the ulcerative colitis therapeutics market.

Increasing Prevalence of Ulcerative Colitis: The market studied has been witnessing considerable growth, which is attributed to the increasing prevalence of inflammatory bowel disease worldwide. According to the estimates, the prevalence of inflammatory bowel disease patients was 910,000 in the United States in 2018.

MARKET TRENDS

High Investment in R&D Activities: Major players in the market are developing products and spending significantly on research and development, along with major acquisitions and collaborations to achieve a competitive edge over their counterparts. High investments in R&D capabilities and infrastructure by the industry and governments are anticipated to create lucrative opportunities in the market.

Presence of Major Players: Companies such as AbbVie, Inc., Pfizer, Inc., Janssen Biotech, Inc. (Johnson & Johnson) are among the major players in the global ulcerative colitis treatment market. These players are focused on adopting organic and inorganic growth strategies to strengthen their product portfolio.

These companies have adopted strategies such as collaborations & acquisitions, expansion of geographical footprint, investments in research & development, and manufacture of novel drugs to compete in the global ulcerative colitis treatment market. The other prominent players operating in the global ulcerative colitis market include Allergan plc, Bausch Health Companies Inc., Takeda Pharmaceutical Company Limited, Novartis AG, Galapogos, and Seres Therapeutics.

Segmentation by Drug Class

TNF-Alpha inhibitors
5-Aminosalicylates
Corticosteroids & Others

Segmentation by Gender Type

Men
Women

Segmentation by Disease Type

Total Colitis
Left-sided Colitis & Proctitis

GEOGRAPHY ANALYSIS

The US dominates the ulcerative colitis market due to the rise in healthcare affordability in the US, the rise in knowledge and awareness amongst the people, and the technological advancement in this region. However, the UK is expected to grow at a faster rate with a high CAGR in the ulcerative colitis drug market due to a rise in access and quality of healthcare, an increase in awareness about disease management, and rising healthcare expenditure in this region. The trend of biosimilars in emerging markets, such as China and Japan, could potentially alter the therapeutic landscape in this region.

Drug Class: Among the drug class, TNF-Alpha inhibitors are expected to account for a significant share of the global ulcerative colitis therapeutics market. However, the other class of drugs is expected to be the fastest-growing segment during the forecast period. Recently approved small molecules such as Jyseleca (filgotinib) and Rinvoq (upadacitinib) are expected to drive the global ulcerative colitis therapeutics market during the forecast period.

Gender type: Among the gender type, Men were expected to account for a significant share of the global ulcerative colitis market. This is due to men being more likely affected than women.

Disease type: Among the Disease type, Total colitis is expected to account for significant ulcerative colitis market share. However, Proctitis is expected to be the fastest-growing segment during the forecast period.

The portfolio contains a total of 106+ assets in various development phases. Most industry-sponsored drugs in active clinical development for ulcerative colitis are in the Phase II stage.

Segmentation by Geography

North America
- US
Europe
- France
- Germany
- Italy
- UK
- Spain
APAC
- China
- Japan

ULCERATIVE COLITIS THERAPEUTICS: CLINICAL TRIALS SCENARIO

The clinical trial portfolio contains 155+ trials in various development phases. Most industry-sponsored drugs in active clinical development for inflammatory bowel disease are in Phase II, with three drugs in the NDA/BLA stage. The distribution of clinical trials across Phase I-IV indicates that the vast majority of trials for ulcerative colitis have been in the early and mid-phases of development, with 84% of trials in Phase I-II and only 16% in Phase III-IV. The US has a substantial lead in the number of ulcerative colitis clinical trials globally.

COMPETITIVE SCENARIO

The Ulcerative Colitis market is dominated by companies offering generic drugs and selective pharma/biotech companies offering patented/commercial drugs for treating UC. The US Food and Drug Administration (FDA) approved the TNF-Alpha agent Humira (Adalimumab) for treating ulcerative colitis in 2012. This marked the arrival of biologics in this treatment landscape. Following this, the FDA approved Jyseleca (filgotinib) and Rinvoq (upadacitinib) in 2022 and Zeposia (ozanimod) in 2021 for the treatment of UC. Although generic products continue to capture significant market share, the arrival of biologics and other targeted therapies indicates a paradigm shift in this therapeutic space through the forecast period.

The inflammatory bowel disease therapeutics portfolio contains a total of 106+ assets in various development phases. Some late-stage emerging inflammatory bowel disease Therapeutics include AJM-300, ontamalimab, CT-P13 SC, SHR-0302, mirikizumab, and others. Launching these novel emerging drugs will shift the inflammatory bowel disease treatment paradigm shortly. With more than 106 molecules in various stages of development, it is expected that new vendors are likely to enter the market with novel mechanisms of action and better safety and efficacy profiles compared to the existing patented commercial drugs for treating ulcerative colitis. Key vendors are likely to face stiff competition from emerging players whose drugs are in various stages of development for UC. Existing vendors need to compete with more than 90 vendors post the approval of their investigational molecules for inflammatory bowel disease treatment in the coming years.

The prominent players offering drugs in the market include Takeda, Abbvie, Janssen Pharmaceuticals, Pfizer, Bristol-Myers-Squibb, EA Pharma Co Ltd, Celltrion, ReiStone Biopharma, Eli Lilly and Company, and Index Pharmaceuticals. These players are focused on R&D initiatives to develop technologically advanced and innovative inflammatory bowel disease treatment drugs and are also entering into collaborations to maintain their market position.

Key Vendors

Johnson & Johnson
AbbVie Inc (AbbVie)
Takeda Pharmaceutical Co Ltd (Takeda)
Pfizer Inc (Pfizer)
Bristol-Myers Squibb
EA Pharma
Eli Lilly and Company
InDex
Reistone Biopharma Co. Ltd.
CellTrion

REPORT COVERAGE

Detailed overview of ulcerative colitis, including disease definition, classification, diagnosis, and treatment pattern
Overview of the global ulcerative colitis market trend in the eight major markets.
Historical, current, and projected patient pool of ulcerative colitis in the eight major markets (8MM) for the 2018 - 2027 period
Gender type, Disease type, Drug Class, and Geography type segmentation of the ulcerative colitis in the eight major markets (8MM)
Historical, current, and projected market size of inflammatory bowel disease treatment market in the eight major markets (8MM) for the 2018 - 2027 period
In-depth analysis of the market segments, which includes products, treatment, and competitor analysis
Market share of the market players, company profiles, product specifications, and competitive landscape
Comprehensive data on emerging trends, market drivers, growth opportunities, and restraints
Detailed overview of marketed drugs with key coverage of developmental activities, including sponsor name, approved indication, territory, collaborations, licensing, mergers and acquisitions, regulatory designations, and other product-related activities
Detailed overview of therapeutic pipeline activity and therapeutic assessment of the products by development stage, product type, route of administration, molecule type, and MOA type for ulcerative colitis across the complete product development cycle, including all clinical and non-clinical stages
Detailed overview of clinical trial activity and therapeutic assessment of the products by development stage, product type, route of administration, molecule type, and Geography type for ulcerative colitis across all clinical stages
Coverage of dormant and discontinued pipeline projects and the reasons for ulcerative colitis.
Coverage of major milestones (product approvals/launches timelines, clinical trial result publications, regulatory designations, licensing & collaborations, research & development progress of pipeline assets) in the ulcerative colitis space.

KEY QUESTIONS ANSWERED

1. HOW BIG IS THE GLOBAL ULCERATIVE COLITIS MARKET?
2. WHAT IS THE GROWTH RATE OF THE GLOBAL ULCERATIVE COLITIS MARKET?
3. WHO ARE THE KEY PLAYERS IN THE ULCERATIVE COLITIS (UC) MARKET?
4. WHAT ARE THE GROWTH FACTORS IN THE ULCERATIVE COLITIS MARKET?

Product Code: ARZ220629

CHAPTER - 1: ULCERATIVE COLITIS OVERVIEW

Ulcerative Colitis - An Overview

CHAPTER - 2: ULCERATIVE COLITIS EPIDEMIOLOGY & OVERVIEW

8MM: Historic & Projected Volume of Incidence & Prevalence of Ulcerative Colitis
8MM: Comparative Analysis of Incidence & Prevalence of Ulcerative Colitis
8MM: Historic & Projected Volume of incidence of Ulcerative Colitis cases by Disease Type
8MM: Historic & Projected Volume of incidence of Ulcerative Colitis cases by Severity Type
8MM: Historic & Projected Volume of Incidence of Ulcerative Colitis cases by Gender & Age Group
8MM: Historic & Projected Volume of Prevalence of Ulcerative Colitis cases by Disease type
8MM: Historic & Projected Volume of Prevalence of Ulcerative Colitis Cases by Severity Type
8MM: Historic & Projected Volume of Prevalence of Ulcerative Colitis Cases by Gender & Age Group
US: Historic & Projected Volume of Incidence & Prevalence of Ulcerative Colitis
US: Comparative Analysis of Incidence & Prevalence of Ulcerative Colitis
US: Historic & Projected Volume of incidence of Ulcerative Colitis Cases by Disease Type
US: Historic & Projected Volume of incidence of Ulcerative Colitis Cases by Severity Type
US: Historic & Projected Volume of Incidence of Ulcerative Colitis Cases by Gender & Age Group
US: Historic & Projected Volume of Prevalence of Ulcerative Colitis Cases by Disease Type
US: Historic & Projected Volume of Prevalence of Ulcerative Colitis Cases by Severity Type
US: Historic & Projected Volume of Prevalence of Ulcerative Colitis Cases by Gender & Age Group
China: Historic & Projected Volume of Incidence & Prevalence of Ulcerative Colitis
China: Comparative Analysis of Incidence & Prevalence of Ulcerative Colitis
China: Historic & Projected Volume of incidence of Ulcerative Colitis Cases by Disease Type
China: Historic & Projected Volume of incidence of Ulcerative Colitis Cases by Severity Type
China: Historic & Projected Volume of Incidence of Ulcerative Colitis Cases by Gender & Age Group
China: Historic & Projected Volume of Prevalence of Ulcerative Colitis Cases by Disease Type
China: Historic & Projected Volume of Prevalence of Ulcerative Colitis Cases by Severity Type
China: Historic & Projected Volume of Prevalence of Ulcerative Colitis Cases by Gender & Age Group
Japan: Historic & Projected Volume of Incidence & Prevalence of Ulcerative Colitis
Japan: Comparative Analysis of Incidence & Prevalence of Ulcerative Colitis
Japan: Historic & Projected Volume of incidence of Ulcerative Colitis Cases by Disease Type
Japan: Historic & Projected Volume of incidence of Ulcerative Colitis Cases by Severity Type
Japan: Historic & Projected Volume of Incidence of Ulcerative Colitis Cases by Gender & Age Group
Japan: Historic & Projected Volume of Prevalence of Ulcerative Colitis Cases by Disease Type
Japan: Historic & Projected Volume of Prevalence of Ulcerative Colitis Cases by Severity Type
Japan: Historic & Projected Volume of Prevalence of Ulcerative Colitis Cases by Gender & Age Group
Germany: Historic & Projected Volume of Incidence & Prevalence of Ulcerative Colitis
Germany: Comparative Analysis of Incidence & Prevalence of Ulcerative Colitis
Germany: Historic & Projected Volume of incidence of Ulcerative Colitis Cases by Disease Type
Germany: Historic & Projected Volume of incidence of Ulcerative Colitis Cases by Severity Type
Germany: Historic & Projected Volume of Incidence of Ulcerative Colitis Cases by Gender & Age Group
Germany: Historic & Projected Volume of Prevalence of Ulcerative Colitis Cases by Disease Type
Germany: Historic & Projected Volume of Prevalence of Ulcerative Colitis Cases by Severity Type
Germany: Historic & Projected Volume of Prevalence of Ulcerative Colitis Cases by Gender & Age Group
UK: Historic & Projected Volume of Incidence & Prevalence of Ulcerative Colitis
UK: Comparative Analysis of Incidence & Prevalence of Ulcerative Colitis
UK: Historic & Projected Volume of incidence of Ulcerative Colitis Cases by Disease Type
UK: Historic & Projected Volume of incidence of Ulcerative Colitis Cases by Severity Type
UK: Historic & Projected Volume of Incidence of Ulcerative Colitis Cases by Gender & Age Group
UK: Historic & Projected Volume of Prevalence of Ulcerative Colitis Cases by Disease Type
UK: Historic & Projected Volume of Prevalence of Ulcerative Colitis Cases by Severity Type
UK: Historic & Projected Volume of Prevalence of Ulcerative Colitis Cases by Gender & Age Group
France: Historic & Projected Volume of Incidence & Prevalence of Ulcerative Colitis
France: Comparative Analysis of Incidence & Prevalence of Ulcerative Colitis
France: Historic & Projected Volume of incidence of Ulcerative Colitis Cases by Disease Type
France: Historic & Projected Volume of incidence of Ulcerative colitis cases by Severity Type
France: Historic & Projected Volume of Incidence of Ulcerative Colitis Cases by Gender & Age Group
France: Historic & Projected Volume of Prevalence of Ulcerative Colitis Cases by Disease Type
France: Historic & Projected Volume of Prevalence of Ulcerative Colitis Cases by Severity Type
France: Historic & Projected Volume of Prevalence of Ulcerative Colitis Cases by Gender & Age Group
Italy: Historic & Projected Volume of Incidence & Prevalence of Ulcerative Colitis
Italy: Comparative Analysis of Incidence & Prevalence of Ulcerative Colitis
Italy: Historic & Projected Volume of incidence of Ulcerative Colitis Cases by Disease Type
Italy: Historic & Projected Volume of incidence of Ulcerative Colitis Cases by Severity Type
Italy: Historic & Projected Volume of Incidence of Ulcerative Colitis Cases by Gender & Age Group
Italy: Historic & Projected Volume of Prevalence of Ulcerative Colitis Cases by Disease Type
Italy: Historic & Projected Volume of Prevalence of Ulcerative Colitis Cases by Severity Type
Italy: Historic & Projected Volume of Prevalence of Ulcerative Colitis Cases by Gender & Age Group
Spain: Historic & Projected Volume of Incidence & Prevalence of Ulcerative Colitis
Spain: Comparative Analysis of Incidence & Prevalence of Ulcerative Colitis
Spain: Historic & Projected Volume of incidence of Ulcerative Colitis Cases by Disease Type
Spain: Historic & Projected Volume of incidence of Ulcerative Colitis Cases by Severity Type
Spain: Historic & Projected Volume of Incidence of Ulcerative Colitis Cases by Gender & Age Group
Spain: Historic & Projected Volume of Prevalence of Ulcerative Colitis Cases by Disease Type
Spain: Historic & Projected Volume of Prevalence of Ulcerative Colitis Cases by Severity Type
Spain: Historic & Projected Volume of Prevalence of Ulcerative Colitis Cases by Gender & Age Group

CHAPTER - 3: ULCERATIVE COLITIS MARKET SIZE & OVERVIEW

8MM: Historic & Projected Revenue of Ulcerative Colitis
8MM: Historic & Projected Revenue of Ulcerative Colitis Snapshot
8MM: Major Approved Drugs in Ulcerative Colitis
8MM: Historic & Projected Revenue Segmentation by Gender Type, Disease Type & Drug Class
US: Historic & Projected Revenue of Ulcerative Colitis
US: Historic & Projected Revenue of Ulcerative Colitis Snapshot
US: Historic & Projected Revenue Segmentation by Gender Type, Disease Type & Drug Class
China: Historic & Projected Revenue of Ulcerative Colitis
China: Historic & Projected Revenue of Ulcerative Colitis Snapshot
China: Historic & Projected Revenue Segmentation by Gender Type, Disease Type,& Drug Class
Japan: Historic & Projected Revenue of Ulcerative Colitis
Japan: Historic & Projected Revenue of Ulcerative Colitis Snapshot
Japan: Historic & Projected Revenue Segmentation by Gender Type, Disease Type & Drug Class
Germany: Historic & Projected Revenue of Ulcerative Colitis
Germany: Historic & Projected Revenue of Ulcerative Colitis Snapshot
Germany: Historic & Projected Revenue Segmentation by Gender Type, Disease Type & Drug Class
UK: Historic & Projected Revenue of Ulcerative Colitis
UK: Historic & Projected Revenue of Ulcerative Colitis Snapshot
UK: Historic & Projected Revenue Segmentation by Gender Type, Disease Type & Drug Class
France: Historic & Projected Revenue of Ulcerative Colitis
France: Historic & Projected Revenue of Ulcerative Colitis Snapshot
France: Historic & Projected Revenue Segmentation by Gender Type, Disease Type & Drug Class
Italy: Historic & Projected Revenue of Ulcerative Colitis
Italy: Historic & Projected Revenue of Ulcerative Colitis Snapshot
Italy: Historic & Projected Revenue Segmentation by Gender Type, Disease Type & Drug Class
Spain: Historic & Projected Revenue of Ulcerative Colitis
Spain: Historic & Projected Revenue of Ulcerative Colitis Snapshot
Spain: Historic & Projected Revenue Segmentation by Gender Type, Disease Type & Drug Class

CHAPTER - 4: ULCERATIVE COLITIS MARKETED DRUGS OVERVIEW

Ulcerative Colitis Marketed Drugs - An Overview
Ulcerative Colitis Marketed Drugs - Summary

CHAPTER - 5: ULCERATIVE COLITIS PIPELINE DRUGS OVERVIEW

Ulcerative Colitis Pipeline Drugs - An Overview
Ulcerative Colitis Pipeline Drugs - Snapshot
Ulcerative Colitis Pipeline Drugs Overview & Snapshot - By Disease type
Ulcerative Colitis Pipeline Drugs Overview & Snapshot - By Development Phase
Ulcerative Colitis Pipeline Drugs Overview & Snapshot - By Route of Administration
Ulcerative Colitis Pipeline Drugs Overview & Snapshot - By Mechanism of Action
Ulcerative Colitis Pipeline Drugs Overview & Snapshot - By Molecule type
Ulcerative Colitis Pipeline Drugs Overview & Snapshot - By Geography type

CHAPTER - 6: ULCERATIVE COLITIS CLINICAL TRIALS OVERVIEW

Ulcerative Colitis Clinical Trials Overview Snapshot
Ulcerative Colitis Clinical Trials Overview - By Recruitment Status
Ulcerative Colitis Clinical Trials Overview - By Product type
Ulcerative Colitis Clinical Trials Overview - By Route of Administration
Ulcerative Colitis Clinical Trials Overview - By Molecule type
Ulcerative Colitis Clinical Trials Overview - By Geography type

CHAPTER - 7: ULCERATIVE COLITIS MARKET DYNAMICS

Ulcerative Colitis Therapeutics Market Drivers
Ulcerative Colitis Therapeutics Market Constraints
Ulcerative Colitis Therapeutics Market Trends

CHAPTER - 8: ULCERATIVE COLITIS COMPETITIVE LANDSCAPE

Ulcerative Colitis Competitive Landscape - Marketed Drugs
Key Company Profiles
Competitive Scenario of Ulcerative colitis therapeutics market
Key Company Snapshot
Ulcerative Colitis Competitive Landscape - Pipeline Drugs
Key Emerging Company Profiles
Key Company Snapshot

CHAPTER - 9: ULCERATIVE COLITIS MISCELLANEOUS

Key Tentative Drug Approvals Timeline
Key Regulatory Designations
Key Milestones
Deals & Collaborations
Inactive/Discontinued/Dormant Products

CHAPTER - 10: APPENDIX

About Arizton
Research Methodology
List of Abbreviations

Product Code: ARZ220629

LIST OF EXHIBITS

Exhibit 1: HISTORIC & PROJECTED VOLUME OF INCIDENCE & PREVALENCE OF ULCERATIVE COLITIS IN 8 MAJOR MARKETS (2018 - 2027)

Exhibit 2: COMPARATIVE ANALYSIS OF INCIDENCE & PREVALENCE OF ULCERATIVE COLITIS IN 8 MAJOR MARKETS (2018 - 2020)

Exhibit 3: COMPARATIVE ANALYSIS OF INCIDENCE & PREVALENCE OF ULCERATIVE COLITIS IN 8 MAJOR MARKETS (2021 - 2027)

Exhibit 4: HISTORIC & PROJECTED VOLUME OF INCIDENCE OF ULCERATIVE COLITIS BY DISEASE TYPE IN 8 MAJOR MARKETS (2018 - 2027)

Exhibit 5: HISTORIC & PROJECTED VOLUME OF INCIDENCE OF ULCERATIVE COLITIS BY SEVERITY TYPE IN 8 MAJOR MARKETS (2018 - 2027)

Exhibit 6: HISTORIC & PROJECTED VOLUME OF INCIDENCE OF ULCERATIVE COLITIS BY AGE GROUP IN 8 MAJOR MARKETS (2018 - 2027)

Exhibit 7: HISTORIC & PROJECTED VOLUME OF INCIDENCE OF ULCERATIVE COLITIS BY GENDER TYPE IN 8 MAJOR MARKETS (2018 - 2027)

Exhibit 8: HISTORIC & PROJECTED VOLUME OF PREVELANCE OF ULCERATIVE COLITIS BY DISEASE TYPE IN 8 MAJOR MARKETS (2018 - 2027)

Exhibit 9: HISTORIC & PROJECTED VOLUME OF PREVALENCE OF ULCERATIVE COLITIS BY SEVERITY TYPE IN 8 MAJOR MARKETS (2018 - 2027)

Exhibit 10: HISTORIC & PROJECTED VOLUME OF PREVALENCE OF ULCERATIVE COLITIS BY AGE GROUP IN 8 MAJOR MARKETS (2018 - 2027)

Exhibit 11: HISTORIC & PROJECTED VOLUME OF PREVALENCE OF ULCERATIVE COLITIS BY GENDER TYPE IN 8 MAJOR MARKETS (2018 - 2027)

Exhibit 12: HISTORIC & PROJECTED VOLUME OF INCIDENCE & PREVALENCE OF ULCERATIVE COLITIS IN US (2018 - 2027)

Exhibit 13: COMPARATIVE ANALYSIS OF INCIDENCE & PREVALENCE OF ULCERATIVE COLITIS IN US (2018 - 2020)

Exhibit 14: COMPARATIVE ANALYSIS OF INCIDENCE & PREVALENCE OF ULCERATIVE COLITIS IN US (2021 - 2027)

Exhibit 15: HISTORIC & PROJECTED VOLUME OF INCIDENCE OF ULCERATIVE COLITIS BY DISEASE TYPE IN US (2018 - 2027)

Exhibit 16: HISTORIC & PROJECTED VOLUME OF INCIDENCE OF ULCERATIVE COLITIS BY SEVERITY TYPE IN US (2018 - 2027)

Exhibit 17: HISTORIC & PROJECTED VOLUME OF INCIDENCE OF ULCERATIVE COLITIS BY AGE GROUP IN US (2018 - 2027)

Exhibit 18: HISTORIC & PROJECTED VOLUME OF INCIDENCE OF ULCERATIVE COLITIS BY GENDER TYPE IN US (2018 - 2027)

Exhibit 19: HISTORIC & PROJECTED VOLUME OF PREVELANCE OF ULCERATIVE COLITIS BY DISEASE TYPE IN US (2018 - 2027)

Exhibit 20: HISTORIC & PROJECTED VOLUME OF PREVALENCE OF ULCERATIVE COLITIS BY SEVERITY TYPE IN US (2018 - 2027)

Exhibit 21: HISTORIC & PROJECTED VOLUME OF PREVALENCE OF ULCERATIVE COLITIS BY AGE GROUP IN US (2018 - 2027)

Exhibit 22: HISTORIC & PROJECTED VOLUME OF PREVALENCE OF ULCERATIVE COLITIS BY GENDER TYPE IN US (2018 - 2027)

Exhibit 23: HISTORIC & PROJECTED VOLUME OF INCIDENCE & PREVALENCE OF ULCERATIVE COLITIS IN CHINA (2018 - 2027)

Exhibit 24: COMPARATIVE ANALYSIS OF INCIDENCE & PREVALENCE OF ULCERATIVE COLITIS IN CHINA (2018 - 2020)

Exhibit 25: COMPARATIVE ANALYSIS OF INCIDENCE & PREVALENCE OF ULCERATIVE COLITIS IN CHINA (2021 - 2027)

Exhibit 26: HISTORIC & PROJECTED VOLUME OF INCIDENCE OF ULCERATIVE COLITIS BY DISEASE TYPE IN CHINA (2018 - 2027)

Exhibit 27: HISTORIC & PROJECTED VOLUME OF INCIDENCE OF ULCERATIVE COLITIS BY SEVERITY TYPE IN CHINA (2018 - 2027)

Exhibit 28: HISTORIC & PROJECTED VOLUME OF INCIDENCE OF ULCERATIVE COLITIS BY AGE GROUP IN CHINA (2018 - 2027)

Exhibit 29: HISTORIC & PROJECTED VOLUME OF INCIDENCE OF ULCERATIVE COLITIS BY GENDER TYPE IN CHINA (2018 - 2027)

Exhibit 30: HISTORIC & PROJECTED VOLUME OF PREVELANCE OF ULCERATIVE COLITIS BY DISEASE TYPE IN CHINA (2018 - 2027)

Exhibit 31: HISTORIC & PROJECTED VOLUME OF PREVALENCE OF ULCERATIVE COLITIS BY SEVERITY TYPE IN CHINA (2018 - 2027)

Exhibit 32: HISTORIC & PROJECTED VOLUME OF PREVALENCE OF ULCERATIVE COLITIS BY AGE GROUP IN CHINA (2018 - 2027)

Exhibit 33: HISTORIC & PROJECTED VOLUME OF PREVALENCE OF ULCERATIVE COLITIS BY GENDER TYPE IN CHINA (2018 - 2027)

Exhibit 34: HISTORIC & PROJECTED VOLUME OF INCIDENCE & PREVALENCE OF ULCERATIVE COLITIS IN JAPAN (2018 - 2027)

Exhibit 35: COMPARATIVE ANALYSIS OF INCIDENCE & PREVALENCE OF ULCERATIVE COLITIS IN JAPAN (2018 - 2020)

Exhibit 36: COMPARATIVE ANALYSIS OF INCIDENCE & PREVALENCE OF ULCERATIVE COLITIS IN JAPAN (2021 - 2027)

Exhibit 37: HISTORIC & PROJECTED VOLUME OF INCIDENCE OF ULCERATIVE COLITIS BY DISEASE TYPE IN JAPAN (2018 - 2027)

Exhibit 38: HISTORIC & PROJECTED VOLUME OF INCIDENCE OF ULCERATIVE COLITIS BY SEVERITY TYPE IN JAPAN (2018 - 2027)

Exhibit 39: HISTORIC & PROJECTED VOLUME OF INCIDENCE OF ULCERATIVE COLITIS BY AGE GROUP IN JAPAN (2018 - 2027)

Exhibit 40: HISTORIC & PROJECTED VOLUME OF INCIDENCE OF ULCERATIVE COLITIS BY GENDER TYPE IN JAPAN (2018 - 2027)

Exhibit 41: HISTORIC & PROJECTED VOLUME OF PREVELANCE OF ULCERATIVE COLITIS BY DISEASE TYPE IN JAPAN (2018 - 2027)

Exhibit 42: HISTORIC & PROJECTED VOLUME OF PREVALENCE OF ULCERATIVE COLITIS BY SEVERITY TYPE IN JAPAN (2018 - 2027)

Exhibit 43: HISTORIC & PROJECTED VOLUME OF PREVALENCE OF ULCERATIVE COLITIS BY AGE GROUP IN JAPAN (2018 - 2027)

Exhibit 44: HISTORIC & PROJECTED VOLUME OF PREVALENCE OF ULCERATIVE COLITIS BY GENDER TYPE IN JAPAN (2018 - 2027)

Exhibit 45: HISTORIC & PROJECTED VOLUME OF INCIDENCE & PREVALENCE OF ULCERATIVE COLITIS IN GERMANY (2018 - 2027)

Exhibit 46: COMPARATIVE ANALYSIS OF INCIDENCE & PREVALENCE OF ULCERATIVE COLITIS IN GERMANY (2018 - 2020)

Exhibit 47: COMPARATIVE ANALYSIS OF INCIDENCE & PREVALENCE OF ULCERATIVE COLITIS IN GERMANY (2021 - 2027)

Exhibit 48: HISTORIC & PROJECTED VOLUME OF INCIDENCE OF ULCERATIVE COLITIS BY DISEASE TYPE IN GERMANY (2018 - 2027)

Exhibit 49: HISTORIC & PROJECTED VOLUME OF INCIDENCE OF ULCERATIVE COLITIS BY SEVERITY TYPE IN GERMANY (2018 - 2027)

Exhibit 50: HISTORIC & PROJECTED VOLUME OF INCIDENCE OF ULCERATIVE COLITIS BY AGE GROUP IN GERMANY (2018 - 2027)

Exhibit 51: HISTORIC & PROJECTED VOLUME OF INCIDENCE OF ULCERATIVE COLITIS BY GENDER TYPE IN GERMANY (2018 - 2027)

Exhibit 52: HISTORIC & PROJECTED VOLUME OF PREVELANCE OF ULCERATIVE COLITIS BY DISEASE TYPE IN GERMANY (2018 - 2027)

Exhibit 53: HISTORIC & PROJECTED VOLUME OF PREVALENCE OF ULCERATIVE COLITIS BY SEVERITY TYPE IN GERMANY (2018 - 2027)

Exhibit 54: HISTORIC & PROJECTED VOLUME OF PREVALENCE OF ULCERATIVE COLITIS BY AGE GROUP IN GERMANY (2018 - 2027)

Exhibit 55: HISTORIC & PROJECTED VOLUME OF PREVALENCE OF ULCERATIVE COLITIS BY GENDER TYPE IN GERMANY (2018 - 2027)

Exhibit 56: HISTORIC & PROJECTED VOLUME OF INCIDENCE & PREVALENCE OF ULCERATIVE COLITIS IN UK (2018 - 2027)

Exhibit 57: COMPARATIVE ANALYSIS OF INCIDENCE & PREVALENCE OF ULCERATIVE COLITIS IN UK (2018 - 2020)

Exhibit 58: COMPARATIVE ANALYSIS OF INCIDENCE & PREVALENCE OF ULCERATIVE COLITIS IN UK (2021 - 2027)

Exhibit 59: HISTORIC & PROJECTED VOLUME OF INCIDENCE OF ULCERATIVE COLITIS BY DISEASE TYPE IN UK (2018 - 2027)

Exhibit 60: HISTORIC & PROJECTED VOLUME OF INCIDENCE OF ULCERATIVE COLITIS BY SEVERITY TYPE IN UK (2018 - 2027)

Exhibit 61: HISTORIC & PROJECTED VOLUME OF INCIDENCE OF ULCERATIVE COLITIS BY AGE GROUP IN UK (2018 - 2027)

Exhibit 62: HISTORIC & PROJECTED VOLUME OF INCIDENCE OF ULCERATIVE COLITIS BY GENDER TYPE IN UK (2018 - 2027)

Exhibit 63: HISTORIC & PROJECTED VOLUME OF PREVELANCE OF ULCERATIVE COLITIS BY DISEASE TYPE IN UK (2018 - 2027)

Exhibit 64: HISTORIC & PROJECTED VOLUME OF PREVALENCE OF ULCERATIVE COLITIS BY SEVERITY TYPE IN UK (2018 - 2027)

Exhibit 65: HISTORIC & PROJECTED VOLUME OF PREVALENCE OF ULCERATIVE COLITIS BY AGE GROUP IN UK (2018 - 2027)

Exhibit 66: HISTORIC & PROJECTED VOLUME OF PREVALENCE OF ULCERATIVE COLITIS BY GENDER TYPE IN UK (2018 - 2027)

Exhibit 67: HISTORIC & PROJECTED VOLUME OF INCIDENCE & PREVALENCE OF ULCERATIVE COLITIS IN FRANCE (2018 - 2027)

Exhibit 68: COMPARATIVE ANALYSIS OF INCIDENCE & PREVALENCE OF ULCERATIVE COLITIS IN FRANCE (2018 - 2020)

Exhibit 69: COMPARATIVE ANALYSIS OF INCIDENCE & PREVALENCE OF ULCERATIVE COLITIS IN FRANCE (2021 - 2027)

Exhibit 70: HISTORIC & PROJECTED VOLUME OF INCIDENCE OF ULCERATIVE COLITIS BY DISEASE TYPE IN FRANCE (2018 - 2027)

Exhibit 71: HISTORIC & PROJECTED VOLUME OF INCIDENCE OF ULCERATIVE COLITIS BY SEVERITY TYPE IN FRANCE (2018 - 2027)

Exhibit 72: HISTORIC & PROJECTED VOLUME OF INCIDENCE OF ULCERATIVE COLITIS BY AGE GROUP IN FRANCE (2018 - 2027)

Exhibit 73: HISTORIC & PROJECTED VOLUME OF INCIDENCE OF ULCERATIVE COLITIS BY GENDER TYPE IN FRANCE (2018 - 2027)

Exhibit 74: HISTORIC & PROJECTED VOLUME OF PREVELANCE OF ULCERATIVE COLITIS BY DISEASE TYPE IN FRANCE (2018 - 2027)

Exhibit 75: HISTORIC & PROJECTED VOLUME OF PREVALENCE OF ULCERATIVE COLITIS BY SEVERITY TYPE IN FRANCE (2018 - 2027)

Exhibit 76: HISTORIC & PROJECTED VOLUME OF PREVALENCE OF ULCERATIVE COLITIS BY AGE GROUP IN FRANCE (2018 - 2027)

Exhibit 77: HISTORIC & PROJECTED VOLUME OF PREVALENCE OF ULCERATIVE COLITIS BY GENDER TYPE IN FRANCE (2018 - 2027)

Exhibit 78: HISTORIC & PROJECTED VOLUME OF INCIDENCE & PREVALENCE OF ULCERATIVE COLITIS IN ITALY (2018 - 2027)

Exhibit 79: COMPARATIVE ANALYSIS OF INCIDENCE & PREVALENCE OF ULCERATIVE COLITIS IN ITALY (2018 - 2020)

Exhibit 80: COMPARATIVE ANALYSIS OF INCIDENCE & PREVALENCE OF ULCERATIVE COLITIS IN ITALY (2021 - 2027)

Exhibit 81: HISTORIC & PROJECTED VOLUME OF INCIDENCE OF ULCERATIVE COLITIS BY DISEASE TYPE IN ITALY (2018 - 2027)

Exhibit 82: HISTORIC & PROJECTED VOLUME OF INCIDENCE OF ULCERATIVE COLITIS BY SEVERITY TYPE IN ITALY (2018 - 2027)

Exhibit 83: HISTORIC & PROJECTED VOLUME OF INCIDENCE OF ULCERATIVE COLITIS BY AGE GROUP IN ITALY (2018 - 2027)

Exhibit 84: HISTORIC & PROJECTED VOLUME OF INCIDENCE OF ULCERATIVE COLITIS BY GENDER TYPE IN ITALY (2018 - 2027)

Exhibit 85: HISTORIC & PROJECTED VOLUME OF PREVELANCE OF ULCERATIVE COLITIS BY DISEASE TYPE IN ITALY (2018 - 2027)

Exhibit 86: HISTORIC & PROJECTED VOLUME OF PREVALENCE OF ULCERATIVE COLITIS BY SEVERITY TYPE IN ITALY (2018 - 2027)

Exhibit 87: HISTORIC & PROJECTED VOLUME OF PREVALENCE OF ULCERATIVE COLITIS BY AGE GROUP IN ITALY (2018 - 2027)

Exhibit 88: HISTORIC & PROJECTED VOLUME OF PREVALENCE OF ULCERATIVE COLITIS BY GENDER TYPE IN ITALY (2018 - 2027)

Exhibit 89: HISTORIC & PROJECTED VOLUME OF INCIDENCE & PREVALENCE OF ULCERATIVE COLITIS IN SPAIN (2018 - 2027)

Exhibit 90: COMPARATIVE ANALYSIS OF INCIDENCE & PREVALENCE OF ULCERATIVE COLITIS IN SPAIN (2018 - 2020)

Exhibit 91: COMPARATIVE ANALYSIS OF INCIDENCE & PREVALENCE OF ULCERATIVE COLITIS IN SPAIN (2021 - 2027)

Exhibit 92: HISTORIC & PROJECTED VOLUME OF INCIDENCE OF ULCERATIVE COLITIS BY DISEASE TYPE IN SPAIN (2018 - 2027)

Exhibit 93: HISTORIC & PROJECTED VOLUME OF INCIDENCE OF ULCERATIVE COLITIS BY SEVERITY TYPE IN SPAIN (2018 - 2027)

Exhibit 94: HISTORIC & PROJECTED VOLUME OF INCIDENCE OF ULCERATIVE COLITIS BY AGE GROUP IN SPAIN (2018 - 2027)

Exhibit 95: HISTORIC & PROJECTED VOLUME OF INCIDENCE OF ULCERATIVE COLITIS BY GENDER TYPE IN SPAIN (2018 - 2027)

Exhibit 96: HISTORIC & PROJECTED VOLUME OF PREVELANCE OF ULCERATIVE COLITIS BY DISEASE TYPE IN SPAIN (2018 - 2027)

Exhibit 97: HISTORIC & PROJECTED VOLUME OF PREVALENCE OF ULCERATIVE COLITIS BY SEVERITY TYPE IN SPAIN (2018 - 2027)

Exhibit 98: HISTORIC & PROJECTED VOLUME OF PREVALENCE OF ULCERATIVE COLITIS BY AGE GROUP IN SPAIN (2018 - 2027)

Exhibit 99: HISTORIC & PROJECTED VOLUME OF PREVALENCE OF ULCERATIVE COLITIS BY GENDER TYPE IN SPAIN (2018 - 2027)

Exhibit 100: HISTORIC & PROJECTED REVENUE OF ULCERATIVE COLITIS THERAPEUTICS MARKET IN 8 MAJOR MARKETS (2021 - 2027)

Exhibit 101: HISTORIC & PROJECTED REVENUE OF ULCERATIVE COLITIS THERAPEUTICS MARKET SNAPSHOT IN 8 MAJOR MARKETS (2018 - 2020)

Exhibit 102: HISTORIC & PROJECTED REVENUE OF ULCERATIVE COLITIS THERAPEUTICS MARKET BY DISEASE TYPE IN 8 MAJOR MARKETS (2021 - 2027)

Exhibit 103: HISTORIC & PROJECTED REVENUE OF ULCERATIVE COLITIS THERAPEUTICS MARKET BY GENDER TYPE IN 8 MAJOR MARKETS (2021 - 2027)

Exhibit 104: HISTORIC & PROJECTED REVENUE OF ULCERATIVE COLITIS THERAPEUTICS MARKET BY DRUG CLASS IN 8 MAJOR MARKETS (2021 - 2027)

Exhibit 105: HISTORIC & PROJECTED REVENUE OF ULCERATIVE COLITIS THERAPEUTICS MARKET IN US (2021 - 2027)

Exhibit 106: HISTORIC & PROJECTED REVENUE OF ULCERATIVE COLITIS THERAPEUTICS MARKET SNAPSHOT IN US (2018 - 2020)

Exhibit 107: HISTORIC & PROJECTED REVENUE OF ULCERATIVE COLITIS THERAPEUTICS MARKET BY DISEASE TYPE IN US (2021 - 2027)

Exhibit 108: HISTORIC & PROJECTED REVENUE OF ULCERATIVE COLITIS THERAPEUTICS MARKET BY GENDER TYPE IN US (2021 - 2027)

Exhibit 109: HISTORIC & PROJECTED REVENUE OF ULCERATIVE COLITIS THERAPEUTICS MARKET BY DRUG CLASS IN US (2021 - 2027)

Exhibit 110: HISTORIC & PROJECTED REVENUE OF ULCERATIVE COLITIS THERAPEUTICS MARKET IN CHINA (2021 - 2027)

Exhibit 111: HISTORIC & PROJECTED REVENUE OF ULCERATIVE COLITIS THERAPEUTICS MARKET SNAPSHOT IN CHINA (2018 - 2020)

Exhibit 112: HISTORIC & PROJECTED REVENUE OF ULCERATIVE COLITIS THERAPEUTICS MARKET BY DISEASE TYPE IN CHINA (2021 - 2027)

Exhibit 113: HISTORIC & PROJECTED REVENUE OF ULCERATIVE COLITIS THERAPEUTICS MARKET BY GENDER TYPE IN CHINA (2021 - 2027)

Exhibit 114: HISTORIC & PROJECTED REVENUE OF ULCERATIVE COLITIS THERAPEUTICS MARKET BY DRUG CLASS IN CHINA (2021 - 2027)

Exhibit 115: HISTORIC & PROJECTED REVENUE OF ULCERATIVE COLITIS THERAPEUTICS MARKET IN GERMANY (2021 - 2027)

Exhibit 116: HISTORIC & PROJECTED REVENUE OF ULCERATIVE COLITIS THERAPEUTICS MARKET SNAPSHOT IN GERMANY (2018 - 2020)

Exhibit 117: HISTORIC & PROJECTED REVENUE OF ULCERATIVE COLITIS THERAPEUTICS MARKET BY DISEASE TYPE IN GERMANY (2021 - 2027)

Exhibit 118: HISTORIC & PROJECTED REVENUE OF ULCERATIVE COLITIS THERAPEUTICS MARKET BY GENDER TYPE IN GERMANY (2021 - 2027)

Exhibit 119: HISTORIC & PROJECTED REVENUE OF ULCERATIVE COLITIS THERAPEUTICS MARKET BY DRUG CLASS IN GERMANY (2021 - 2027)

Exhibit 120: HISTORIC & PROJECTED REVENUE OF ULCERATIVE COLITIS THERAPEUTICS MARKET IN JAPAN (2021 - 2027)

Exhibit 121: HISTORIC & PROJECTED REVENUE OF ULCERATIVE COLITIS THERAPEUTICS MARKET SNAPSHOT IN JAPAN (2018 - 2020)

Exhibit 122: HISTORIC & PROJECTED REVENUE OF ULCERATIVE COLITIS THERAPEUTICS MARKET BY DISEASE TYPE IN JAPAN (2021 - 2027)

Exhibit 123: HISTORIC & PROJECTED REVENUE OF ULCERATIVE COLITIS THERAPEUTICS MARKET BY GENDER TYPE IN JAPAN (2021 - 2027)

Exhibit 124: HISTORIC & PROJECTED REVENUE OF ULCERATIVE COLITIS THERAPEUTICS MARKET BY DRUG CLASS IN JAPAN (2021 - 2027)

Exhibit 125: HISTORIC & PROJECTED REVENUE OF ULCERATIVE COLITIS THERAPEUTICS MARKET IN FRANCE (2021 - 2027)

Exhibit 126: HISTORIC & PROJECTED REVENUE OF ULCERATIVE COLITIS THERAPEUTICS MARKET SNAPSHOT IN FRANCE (2018 - 2020)

Exhibit 127: HISTORIC & PROJECTED REVENUE OF ULCERATIVE COLITIS THERAPEUTICS MARKET BY DISEASE TYPE IN FRANCE (2021 - 2027)

Exhibit 128: HISTORIC & PROJECTED REVENUE OF ULCERATIVE COLITIS THERAPEUTICS MARKET BY GENDER TYPE IN FRANCE (2021 - 2027)

Exhibit 129: HISTORIC & PROJECTED REVENUE OF ULCERATIVE COLITIS THERAPEUTICS MARKET BY DRUG CLASS IN FRANCE (2021 - 2027)

Exhibit 130: HISTORIC & PROJECTED REVENUE OF ULCERATIVE COLITIS THERAPEUTICS MARKET IN ITALY (2021 - 2027)

Exhibit 131: HISTORIC & PROJECTED REVENUE OF ULCERATIVE COLITIS THERAPEUTICS MARKET SNAPSHOT IN ITALY (2018 - 2020)

Exhibit 132: HISTORIC & PROJECTED REVENUE OF ULCERATIVE COLITIS THERAPEUTICS MARKET BY DISEASE TYPE IN ITALY (2021 - 2027)

Exhibit 133: HISTORIC & PROJECTED REVENUE OF ULCERATIVE COLITIS THERAPEUTICS MARKET BY GENDER TYPE IN ITALY (2021 - 2027)

Exhibit 134: HISTORIC & PROJECTED REVENUE OF ULCERATIVE COLITIS THERAPEUTICS MARKET BY DRUG CLASS IN ITALY (2021 - 2027)

Exhibit 135: HISTORIC & PROJECTED REVENUE OF ULCERATIVE COLITIS THERAPEUTICS MARKET IN UK (2021 - 2027)

Exhibit 136: HISTORIC & PROJECTED REVENUE OF ULCERATIVE COLITIS THERAPEUTICS MARKET SNAPSHOT IN UK (2018 - 2020)

Exhibit 137: HISTORIC & PROJECTED REVENUE OF ULCERATIVE COLITIS THERAPEUTICS MARKET BY DISEASE TYPE IN UK (2021 - 2027)

Exhibit 138: HISTORIC & PROJECTED REVENUE OF ULCERATIVE COLITIS THERAPEUTICS MARKET BY GENDER TYPE IN UK (2021 - 2027)

Exhibit 139: HISTORIC & PROJECTED REVENUE OF ULCERATIVE COLITIS THERAPEUTICS MARKET BY DRUG CLASS IN UK (2021 - 2027)

Exhibit 140: HISTORIC & PROJECTED REVENUE OF ULCERATIVE COLITIS THERAPEUTICS MARKET IN SPAIN (2021 - 2027)

Exhibit 141: HISTORIC & PROJECTED REVENUE OF ULCERATIVE COLITIS THERAPEUTICS MARKET SNAPSHOT IN SPAIN (2018 - 2020)

Exhibit 142: HISTORIC & PROJECTED REVENUE OF ULCERATIVE COLITIS THERAPEUTICS MARKET BY DISEASE TYPE IN SPAIN (2021 - 2027)

Exhibit 143: HISTORIC & PROJECTED REVENUE OF ULCERATIVE COLITIS THERAPEUTICS MARKET BY GENDER TYPE IN SPAIN (2021 - 2027)

Exhibit 144: HISTORIC & PROJECTED REVENUE OF ULCERATIVE COLITIS THERAPEUTICS MARKET BY DRUG CLASS IN SPAIN (2021 - 2027)

Exhibit 145: MARKETED DRUGS OVERVIEW IN ULCERATIVE COLITIS THERAPEUTICS MARKET

Exhibit 146: MARKETED DRUGS OVERVIEW SNAPSHOT IN ULCERATIVE COLITIS THERAPEUTICS MARKET

Exhibit 147: PIPELINE DRUGS OVERVIEW IN ULCERATIVE COLITIS THERAPEUTICS MARKET

Exhibit 148: ULCERATIVE COLITIS PIPELINE DRUGS OVERVIEW BY DISEASE TYPE

Exhibit 149: ULCERATIVE COLITIS PIPELINE DRUGS OVERVIEW BY DEVELOPMENT PHASE

Exhibit 150: ULCERATIVE COLITIS PIPELINE DRUGS OVERVIEW BY ROUTE OF ADMINISTRATION

Exhibit 151: ULCERATIVE COLITIS PIPELINE DRUGS OVERVIEW BY MECHANISM OF ACTION

Exhibit 152: ULCERATIVE COLITIS PIPELINE DRUGS OVERVIEW BY MOLECULE TYPE

Exhibit 153: ULCERATIVE COLITIS PIPELINE DRUGS OVERVIEW BY GEOGRAPHY TYPE

Exhibit 154: ULCERATIVE COLITIS CLINICAL TRIAL ANALYSIS SNAPSHOT

Exhibit 155: ULCERATIVE COLITIS CLINICAL TRIAL ANALYSIS SNAPSHOT BY RECRUITMENT STATUS

Exhibit 156: ULCERATIVE COLITIS CLINICAL TRIAL ANALYSIS SNAPSHOT BY PRODUCT TYPE

Exhibit 157: ULCERATIVE COLITIS CLINICAL TRIAL ANALYSIS SNAPSHOT BY ROUTE OF ADMINISTRATION

Exhibit 158: ULCERATIVE COLITIS CLINICAL TRIAL ANALYSIS SNAPSHOT BY MOLECULE TYPE

Exhibit 159: ULCERATIVE COLITIS CLINICAL TRIAL ANALYSIS SNAPSHOT BY GEOGRAPHY TYPE

Exhibit 160: COMPETITIVE ASSESSMENT OF ULCERATIVE COLITIS THERAPEUTICS MARKET

LIST OF TABLES

Table 1: KEY MARKET DRIVERS IN ULCERATIVE COLITIS THERAPEUTICS MARKET

Table 2: KEY MARKET CONSTRAINTS IN ULCERATIVE COLITIS THERAPEUTICS MARKET

Table 3: KEY MARKET TRENDS IN ULCERATIVE COLITIS THERAPEUTICS MARKET

Table 4: KEY TENTATIVE TIMELINE APPROVALS OF PIPELINE DRUHS IN ULCERATIVE COLITIS

Table 5: KEY REGULATORY DESIGNATIONS OF PIPELINE DRUHS IN ULCERATIVE COLITIS

Table 6: KEY MILESTONES IN ULCERATIVE COLITIS THERAPEUTICS MARKET

Table 7: KEY DEALS & COLLABORATIONS IN ULCERATIVE COLITIS THERAPEUTICS MARKET

Table 8: KEY INACTIVE/DISCONTINUED PRODUCTS IN ULCERATIVE COLITIS THERAPEUTICS MARKET

Ulcerative Colitis Market Forecast - Epidemiology & Pipeline Analysis 2022-2027

Description

Table of Contents

List of Tables

TABLE OF CONTENTS

LIST OF EXHIBITS